

Indian Accounting Standard (Ind AS-24) " Related Party Disclosures "

Names of related parties and description of relationship

1. Key Management Personnel

Dilip S. Shanghvi	Chairman & Managing Director
Sudhir V. Valia	Non Executive Director
Rajamannar Tennati	Non-Executive Director
Bhavna Doshi	Independent Director
Ferzaan Engineer	Independent Director
Mark J. Simon	Independent Director (Retired on February 28, 2020)

2. Holding Company

Shanghvi Finance Private Limited

3. Enterprise under Significant Influence of Key Management Personnel (with whom transactions are entered)

Sun Pharmaceutical Industries Limited	Aditya Imaging Information Technologies Pvt. Ltd.
Sun Pharma Laboratories Limited	(Earlier known as Aditya Imaging Information Technologies LLP)
Sun Pharma Global FZE	Alkaloida Chemical Company ZRT
Sun Pharmaceutical Industries Inc.	Taro Pharmaceuticals Industries Limited
Sun Pharmaceutical Medicare Limited	Insite Vision Inc.
Sun Pharmaceutical Industries Europe BV	

Rs. In Lakhs

Particulars	Half Year ended March 31, 2020
Aditya Imaging Information Technologies Pvt. Ltd. (wef March 2, 2020) (Previously known as Aditya Imaging Information Technologies LLP)	
Reimbursement of expenses received	3.48
Alkaloida Chemical Company ZRT	
Purchase of goods	(0.10)
Mark J. Simon	
Receiving of research and development services	22.01
Director sitting fees	2.70
Sun Pharma Global FZE	
Sale of services - License fees / Royalty on technology / R&D services	395.87
Sun Pharma Laboratories Limited	
Sale of services - License fees / Royalty on technology / R&D services	1,525.07
Purchase of goods	0.60
Sun Pharmaceutical Industries Europe BV	
Purchase of goods	5.94
Sun Pharmaceutical Industries Inc.	
Sale of services - License fees / Royalty on technology / R&D services	9.98
Reimbursement / Receiving of research and development services	1,277.13
Purchase of goods	35.42

Sun Pharmaceutical Industries Limited	
Sale of services - License fees / Royalty on technology / R&D services	2,297.41
Purchase of goods	77.97
Purchase of property, plant & equipment	47.52
Rent expense	101.47
Receiving of research and development services	436.09
Reimbursement of expenses paid	185.30
Reimbursement of expenses received	44.82
Sun Pharmaceutical Medicare Limited	
Reimbursement of expenses received	-
Purchase of property, plant & equipment	0.60
Purchase of goods	2.34
Taro Pharmaceuticals Industries Limited	
Sale of services - R&D services	1.68
Receiving of research and development services	0.35
Insite Vision	
Purchase of property, plant & equipment	0.92
Shanghvi Finance Private Limited	
Loan received	6,000.00
Interest paid	146.02
Sudhir V. Valia	
Director sitting fees	2.70
Bhavna Doshi	
Director sitting fees	3.00
Rajamannar Tennati	
Director sitting fees	1.20
Ferzaan Engineer	
Director sitting fees	2.70

Balance outstanding - Receivable / (Payable)

Rs. In Lakhs

Particulars	As at Mar 31, 2020
Sun Pharma Global FZE	184.26
Sun Pharma Laboratories Limited	812.82
Sun Pharmaceutical Industries Europe BV	(57.64)
Sun Pharmaceutical Industries Inc.	(5,498.62)
Sun Pharmaceutical Industries Limited	550.77
Sun Pharmaceutical Medicare Limited	5.24
Taro Pharmaceuticals Industries Limited	0.64
Shanghvi Finance Private Limited	(6,000.00)
Mark J. Simon	(22.00)
Insite Vision	(0.98)

Terms and condition of transaction with related parties.

The sale of services to related parties are made on terms equivalent to those that prevail in arms length transactions. Outstanding balances as on 31st March 2020 are unsecured and interest free and settlement occurs in cash. There have been no guarantees provided or received for any related parties receivables or payable.

Chetan M. Rajpara
Chief Financial Officer